首页 > 最新文献

Gynecological Endocrinology最新文献

英文 中文
Correction. 更正。
IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-12-01 Epub Date: 2024-07-22 DOI: 10.1080/09513590.2024.2378582
{"title":"Correction.","authors":"","doi":"10.1080/09513590.2024.2378582","DOIUrl":"https://doi.org/10.1080/09513590.2024.2378582","url":null,"abstract":"","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2378582"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141733895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Network meta-analysis of four common immunomodulatory therapies for the treatment of patients with thin endometrium. 治疗子宫内膜薄患者的四种常见免疫调节疗法的网络荟萃分析。
IF 2 4区 医学 Q2 Medicine Pub Date : 2024-12-01 Epub Date: 2024-06-05 DOI: 10.1080/09513590.2024.2360072
Lifei Li, Zhijian Kou, Fei Zhao, Yan Wang, Xuehong Zhang

Obejective: To compare the effectiveness of endometrial receptivity and pregnancy outcomes of four common immunomodulatory therapies for patients with thin endometrium.

Method: This systematic review and network meta-analysis using a literature search up to January 2024, to identify relevant trials comparing endometrial receptivity and pregnancy outcomes of human chorionic gonadotropin (hCG), platelet-rich plasma (PRP), infusion of granulocyte colony-stimulating factor (IG-CSF), and peripheral blood mononuclear cell (PBMC) for patients with thin endometrium. We used surface under the cumulative ranking (SUCRA) to ranked four common immunomodulatory therapies on endometrium thickness, implantation rate (IR), clinical pregnancy rate (CPR), and live birth rate (LBR). RoB2 and ROBINS-I were used to assess the certainty of evidence.

Results: The pooled results of 22 studies showed that hCG (mean difference [MD]: 3.05, 95% confidence interval [CI]: 1.46-4.64) and PRP (MD: 0.98, 95% CI: 0.20-1.76) significantly increase endometrium thickness. The hCG was the best among the IG-CSF (MD = -2.56, 95% CI = -4.30 to -0.82), PBMC (MD = -2.75, 95% CI = -5.49 to -0.01), and PRP (MD = -2.07, 95% CI = -3.84 to -0.30) in increasing endometrium thickness. However, IG-CSF and PRP significantly improved IR (IG-CSF: risk ratio (RR; IG-CSF: RR = 1.33, 95% CI = 1.06-1.67; PRP: RR = 1.63, 95% CI = 1.19-2.23), and LBR (IG-CSF: RR = 1.53, 95% CI = 1.16-2.02; PRP: RR = 1.59, 95% CI = 1.08-2.36).

Conclusions: Available evidence reveals that hCG and subcutaneous or intrauterine CSF (SG-CSF) may be the best treatment options for current thin endometrium patients. However, future high-quality and large-scale studies are necessary to validate our findings.

目的比较四种常见免疫调节疗法对子宫内膜薄患者的子宫内膜受孕率和妊娠结局的有效性:本系统综述和网络荟萃分析使用截至2024年1月的文献检索,以确定比较人绒毛膜促性腺激素(hCG)、富血小板血浆(PRP)、输注粒细胞集落刺激因子(IG-CSF)和外周血单核细胞(PBMC)对子宫内膜薄患者的子宫内膜受孕率和妊娠结局的相关试验。我们使用表面累积排名(SUCRA)对四种常见免疫调节疗法对子宫内膜厚度、着床率(IR)、临床妊娠率(CPR)和活产率(LBR)的影响进行了排名。采用RoB2和ROBINS-I评估证据的确定性:22项研究的汇总结果显示,hCG(平均差[MD]:3.05,95%置信区间[CI]:1.46-4.64)和PRP(平均差[MD]:0.98,95%置信区间[CI]:0.20-1.76)能显著增加子宫内膜厚度。在 IG-CSF(MD = -2.56,95% CI = -4.30--0.82)、PBMC(MD = -2.75,95% CI = -5.49--0.01)和 PRP(MD = -2.07,95% CI = -3.84--0.30)中,hCG 增加子宫内膜厚度的效果最好。然而,IG-CSF 和 PRP 能显著改善 IR(IG-CSF:风险比 (RR;IG-CSF:RR = 1.33,95% CI = 1.06-1.67;PRP:RR = 1.63,95% CI = 1.19-2.23)和 LBR(IG-CSF:RR = 1.53,95% CI = 1.16-2.02;PRP:RR = 1.59,95% CI = 1.08-2.36):现有证据显示,hCG 和皮下或宫腔内 CSF(SG-CSF)可能是目前子宫内膜薄患者的最佳治疗方案。然而,未来有必要开展高质量的大规模研究来验证我们的发现。
{"title":"Network meta-analysis of four common immunomodulatory therapies for the treatment of patients with thin endometrium.","authors":"Lifei Li, Zhijian Kou, Fei Zhao, Yan Wang, Xuehong Zhang","doi":"10.1080/09513590.2024.2360072","DOIUrl":"10.1080/09513590.2024.2360072","url":null,"abstract":"<p><strong>Obejective: </strong>To compare the effectiveness of endometrial receptivity and pregnancy outcomes of four common immunomodulatory therapies for patients with thin endometrium.</p><p><strong>Method: </strong>This systematic review and network meta-analysis using a literature search up to January 2024, to identify relevant trials comparing endometrial receptivity and pregnancy outcomes of human chorionic gonadotropin (hCG), platelet-rich plasma (PRP), infusion of granulocyte colony-stimulating factor (IG-CSF), and peripheral blood mononuclear cell (PBMC) for patients with thin endometrium. We used surface under the cumulative ranking (SUCRA) to ranked four common immunomodulatory therapies on endometrium thickness, implantation rate (IR), clinical pregnancy rate (CPR), and live birth rate (LBR). RoB2 and ROBINS-I were used to assess the certainty of evidence.</p><p><strong>Results: </strong>The pooled results of 22 studies showed that hCG (mean difference [MD]: 3.05, 95% confidence interval [CI]: 1.46-4.64) and PRP (MD: 0.98, 95% CI: 0.20-1.76) significantly increase endometrium thickness. The hCG was the best among the IG-CSF (MD = -2.56, 95% CI = -4.30 to -0.82), PBMC (MD = -2.75, 95% CI = -5.49 to -0.01), and PRP (MD = -2.07, 95% CI = -3.84 to -0.30) in increasing endometrium thickness. However, IG-CSF and PRP significantly improved IR (IG-CSF: risk ratio (RR; IG-CSF: RR = 1.33, 95% CI = 1.06-1.67; PRP: RR = 1.63, 95% CI = 1.19-2.23), and LBR (IG-CSF: RR = 1.53, 95% CI = 1.16-2.02; PRP: RR = 1.59, 95% CI = 1.08-2.36).</p><p><strong>Conclusions: </strong>Available evidence reveals that hCG and subcutaneous or intrauterine CSF (SG-CSF) may be the best treatment options for current thin endometrium patients. However, future high-quality and large-scale studies are necessary to validate our findings.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2360072"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141247860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Menstrual pattern in polycystic ovary syndrome and hypothalamic-pituitary-ovarian axis immaturity in adolescents: a systematic review and meta-analysis. 青少年多囊卵巢综合征和下丘脑-垂体-卵巢轴不成熟的月经模式:系统综述和荟萃分析。
IF 2 4区 医学 Q2 Medicine Pub Date : 2024-12-01 Epub Date: 2024-05-31 DOI: 10.1080/09513590.2024.2360077
Lea T S Zuchelo, Mayara S Alves, Edmund C Baracat, Isabel C E Sorpreso, José M Soares

Objective: To analyze differences in the menstrual pattern, age at menarche, and body mass index (BMI) in adolescents with Hypothalamic-Pituitary-Ovarian (HPO) axis immaturity and Polycystic Ovary Syndrome (PCOS) through a systematic review and meta-analysis.

Methods: The PubMed, EMBASE, Web of Science, Virtual Health Library, Scopus databases were searched using combinations of descriptors. Study quality was assessed using the Newcastle-Ottawa Scale. For data analysis, the results were grouped into PCOS group and NPCOS group (HPO axis immaturity). We performed a meta-analysis of raw data and the inverse variance method, employing the standardized mean difference, of the age at menarche and BMI of adolescents.

Results: Participants totaled 1,718 from nine selected studies. The meta-analysis showed that the PCOS group had a higher BMI than the NPCOS group (SMD 0.334; CI95% 0.073 - 0.595; p = .012). The degree of heterogeneity of the studies was approximately 40%. No significant difference in age at menarche (SMD - 0.027; CI95% -0.227 - 0.172; p = 0.790) and menstrual patterns was found, but amenorrhea was described only in adolescents with PCOS.

Conclusions: The main characteristic in menstrual pattern that differentiated PCOS patients from girls with HPO axis immaturity was amenorrhea. Also, the BMI of PCOS patients was nearly one third higher than that of adolescents with HPO axis immaturity.

目的通过系统综述和荟萃分析,分析下丘脑-垂体-卵巢(HPO)轴不成熟和多囊卵巢综合征(PCOS)青少年在月经模式、初潮年龄和体重指数(BMI)方面的差异:方法:使用描述符组合检索 PubMed、EMBASE、Web of Science、Virtual Health Library 和 Scopus 数据库。研究质量采用纽卡斯尔-渥太华量表进行评估。在数据分析中,研究结果被分为 PCOS 组和 NPCOS 组(HPO 轴不成熟)。我们对原始数据进行了荟萃分析,并采用反方差法对青少年的初潮年龄和体重指数进行了标准化均差分析:共有 1 718 人参加了 9 项选定的研究。荟萃分析表明,多囊卵巢综合征组的 BMI 高于 NPCOS 组(SMD 0.334;CI95% 0.073 - 0.595;P = .012)。研究的异质性程度约为 40%。月经初潮年龄(SMD - 0.027; CI95% -0.227 - 0.172; p = 0.790)和月经模式无明显差异,但只有患有多囊卵巢综合征的青少年出现闭经:结论:将多囊卵巢综合征患者与 HPO 轴不成熟的女孩区分开来的主要月经模式特征是闭经。此外,多囊卵巢综合征患者的体重指数比HPO轴不成熟的青少年高出近三分之一。
{"title":"Menstrual pattern in polycystic ovary syndrome and hypothalamic-pituitary-ovarian axis immaturity in adolescents: a systematic review and meta-analysis.","authors":"Lea T S Zuchelo, Mayara S Alves, Edmund C Baracat, Isabel C E Sorpreso, José M Soares","doi":"10.1080/09513590.2024.2360077","DOIUrl":"10.1080/09513590.2024.2360077","url":null,"abstract":"<p><strong>Objective: </strong>To analyze differences in the menstrual pattern, age at menarche, and body mass index (BMI) in adolescents with Hypothalamic-Pituitary-Ovarian (HPO) axis immaturity and Polycystic Ovary Syndrome (PCOS) through a systematic review and meta-analysis.</p><p><strong>Methods: </strong>The PubMed, EMBASE, Web of Science, Virtual Health Library, Scopus databases were searched using combinations of descriptors. Study quality was assessed using the Newcastle-Ottawa Scale. For data analysis, the results were grouped into PCOS group and NPCOS group (HPO axis immaturity). We performed a meta-analysis of raw data and the inverse variance method, employing the standardized mean difference, of the age at menarche and BMI of adolescents.</p><p><strong>Results: </strong>Participants totaled 1,718 from nine selected studies. The meta-analysis showed that the PCOS group had a higher BMI than the NPCOS group (SMD 0.334; CI95% 0.073 - 0.595; <i>p</i> = .012). The degree of heterogeneity of the studies was approximately 40%. No significant difference in age at menarche (SMD - 0.027; CI95% -0.227 - 0.172; <i>p</i> = 0.790) and menstrual patterns was found, but amenorrhea was described only in adolescents with PCOS.</p><p><strong>Conclusions: </strong>The main characteristic in menstrual pattern that differentiated PCOS patients from girls with HPO axis immaturity was amenorrhea. Also, the BMI of PCOS patients was nearly one third higher than that of adolescents with HPO axis immaturity.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2360077"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Telomerase activity, telomere length, and the euploidy rate of human embryos. 端粒酶活性、端粒长度和人类胚胎的非整倍体率。
IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-12-01 Epub Date: 2024-07-01 DOI: 10.1080/09513590.2024.2373742
Maria Longo, Ermanno Greco, Ilaria Listorti, Maria Teresa Varricchio, Katerina Litwicka, Cristiana Arrivi, Cecilia Mencacci, Pierfrancesco Greco

Background: Telomeres maintain chromosome stability, while telomerase counteracts their progressive shortening. Telomere length varies between cell types, with leukocyte telomere length (LTL) decreasing with age. Reduced telomerase activity has been linked to reproductive issues in females, such as low pregnancy rates and premature ovarian failure, with recent studies indicating correlations between telomere length in granulosa cells and IVF outcomes.

Objectives: The study aims to explore the relationship between telomere length, telomerase activity, and euploid blastocyst rate in infertile women undergoing IVF/ICSI PGT-A cycles.

Methods: This prospective study involves 108 patients undergoing controlled ovarian stimulation and PGT-A. Telomere length and telomerase activity were measured in peripheral mononuclear cells and granulosa cells (GC), respectively.

Results: The telomere repeat copy number to single gene copy number ratio (T/S) results respectively 0.6 ± 0.8 in leukocytes and 0.7 ± 0.9 in GC. An inverse relationship was found between LTL and the patient's age (p < .01). A higher aneuploid rate was noticed in patients with short LTL, with no differences in ovarian reserve markers (p = .15), number of oocytes retrieved (p = .33), and number of MII (p = 0.42). No significant association was noticed between telomere length in GC and patients' age (p = 0.95), in ovarian reserve markers (p = 0.32), number of oocytes retrieved (p = .58), number of MII (p = .74) and aneuploidy rate (p = .65).

Conclusion: LTL shows a significant inverse correlation with patient age and higher aneuploidy rates. Telomere length in GCs does not correlate with patient age or reproductive outcomes, indicating differential telomere dynamics between leukocytes and granulosa cells.

背景端粒能维持染色体的稳定性,而端粒酶则能抵消端粒的逐渐缩短。端粒长度因细胞类型而异,白细胞端粒长度(LTL)随年龄增长而减少。端粒酶活性降低与女性生殖问题有关,如怀孕率低和卵巢早衰,最近的研究表明颗粒细胞端粒长度与试管婴儿结果之间存在相关性:本研究旨在探讨接受IVF/ICSI PGT-A周期治疗的不孕女性的端粒长度、端粒酶活性和优倍囊胚率之间的关系:这项前瞻性研究涉及 108 名接受控制性卵巢刺激和 PGT-A 的患者。方法:这项前瞻性研究涉及108名接受控制性卵巢刺激和PGT-A的患者,分别测量了外周单核细胞和颗粒细胞(GC)的端粒长度和端粒酶活性:结果:端粒重复拷贝数与单基因拷贝数之比(T/S)分别为:白细胞 0.6 ± 0.8,粒细胞 0.7 ± 0.9。发现LTL与患者年龄(p = .15)、取卵数量(p = .33)和MII数量(p = 0.42)呈反向关系。GC的端粒长度与患者的年龄(p = 0.95)、卵巢储备指标(p = 0.32)、取卵细胞数(p = .58)、MII数(p = .74)和非整倍体率(p = .65)均无明显关联:结论:LTL与患者年龄和较高的非整倍体率呈明显的反相关。GC的端粒长度与患者年龄或生殖结果无关,这表明白细胞和颗粒细胞的端粒动态存在差异。
{"title":"Telomerase activity, telomere length, and the euploidy rate of human embryos.","authors":"Maria Longo, Ermanno Greco, Ilaria Listorti, Maria Teresa Varricchio, Katerina Litwicka, Cristiana Arrivi, Cecilia Mencacci, Pierfrancesco Greco","doi":"10.1080/09513590.2024.2373742","DOIUrl":"https://doi.org/10.1080/09513590.2024.2373742","url":null,"abstract":"<p><strong>Background: </strong>Telomeres maintain chromosome stability, while telomerase counteracts their progressive shortening. Telomere length varies between cell types, with leukocyte telomere length (LTL) decreasing with age. Reduced telomerase activity has been linked to reproductive issues in females, such as low pregnancy rates and premature ovarian failure, with recent studies indicating correlations between telomere length in granulosa cells and IVF outcomes.</p><p><strong>Objectives: </strong>The study aims to explore the relationship between telomere length, telomerase activity, and euploid blastocyst rate in infertile women undergoing IVF/ICSI PGT-A cycles.</p><p><strong>Methods: </strong>This prospective study involves 108 patients undergoing controlled ovarian stimulation and PGT-A. Telomere length and telomerase activity were measured in peripheral mononuclear cells and granulosa cells (GC), respectively.</p><p><strong>Results: </strong>The telomere repeat copy number to single gene copy number ratio (T/S) results respectively 0.6 ± 0.8 in leukocytes and 0.7 ± 0.9 in GC. An inverse relationship was found between LTL and the patient's age (<i>p</i> < .01). A higher aneuploid rate was noticed in patients with short LTL, with no differences in ovarian reserve markers (<i>p</i> = .15), number of oocytes retrieved (<i>p</i> = .33), and number of MII (<i>p</i> = 0.42). No significant association was noticed between telomere length in GC and patients' age (<i>p</i> = 0.95), in ovarian reserve markers (<i>p</i> = 0.32), number of oocytes retrieved (<i>p</i> = .58), number of MII (<i>p</i> = .74) and aneuploidy rate (<i>p</i> = .65).</p><p><strong>Conclusion: </strong>LTL shows a significant inverse correlation with patient age and higher aneuploidy rates. Telomere length in GCs does not correlate with patient age or reproductive outcomes, indicating differential telomere dynamics between leukocytes and granulosa cells.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2373742"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing timing for intrauterine insemination (IUI) in donor sperm cycles: pre- versus post-ovulation insemination in natural cycles. 优化供精周期宫腔内人工授精(IUI)的时机:自然周期排卵前人工授精与排卵后人工授精。
IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-12-01 Epub Date: 2024-10-09 DOI: 10.1080/09513590.2024.2413164
Na Zhang, Hanying Zhou

Purpose: To investigate whether pregnancy outcomes of natural cycle intrauterine insemination (IUI) with donor sperm can be improved by performing insemination after confirmation of ovulation.

Methods: This retrospective cohort study evaluated 751 couples undergoing 1170 cycles of artificial insemination with donor sperm (AID) in natural cycles between January 2018 and January 2021. Patients underwent AID either within 6-12 h after spontaneous luteinizing hormone (LH) surge (pre-ovulation group) or after ovulation was confirmed by ultrasound (post-ovulation group). Propensity score matching was performed to account for differences in baseline characteristics between groups. The main outcome measures of this study were clinical pregnancy rate and live birth rate.

Results: After propensity score matching, each group comprised 216 cycles. No significant differences were observed between the pre-ovulation and post-ovulation groups in terms of clinical pregnancy rate (30.6% vs 27.3%, respectively, p = .458) and live birth rate (25.0% vs 22.7%, respectively, p = .651). However, upon excluding cases of luteinized unruptured follicle syndrome (LUFS) from the pre-ovulation group, the clinical pregnancy rate (33.5% vs 27.3%, respectively, p = .043) and live birth rate (27.4% vs 22.7%, respectively, p = .039) were significantly higher in the pre-ovulation group.

Conclusions: For fertile women undergoing AID in natural cycles, pre-ovulation insemination timing yielded superior pregnancy outcomes compared to post-ovulation insemination when ovulation was achieved. However, due to the occurrence of LUFS, pre- and post-ovulation AID resulted in comparable overall pregnancy outcomes in natural cycles.

目的:研究在确认排卵后进行人工授精是否能改善自然周期供精宫腔内人工授精(IUI)的妊娠结局:这项回顾性队列研究评估了 2018 年 1 月至 2021 年 1 月期间接受 1170 个自然周期供精人工授精(AID)的 751 对夫妇。患者在自发黄体生成素(LH)激增后6-12小时内(排卵前组)或经超声确认排卵后(排卵后组)接受了人工授精。为考虑各组间基线特征的差异,进行了倾向得分匹配。本研究的主要结果指标是临床妊娠率和活产率:经过倾向评分匹配后,每组包括 216 个周期。在临床妊娠率(分别为 30.6% vs 27.3%,P = .458)和活产率(分别为 25.0% vs 22.7%,P = .651)方面,排卵前组和排卵后组之间未发现明显差异。然而,在排除排卵前组黄素化未破裂卵泡综合征(LUFS)病例后,排卵前组的临床妊娠率(分别为33.5% vs 27.3%,p = .043)和活产率(分别为27.4% vs 22.7%,p = .039)显著高于排卵前组:结论:对于在自然周期中接受人工授精的育龄妇女而言,与排卵后人工授精相比,排卵前人工授精的妊娠结局更为理想。然而,由于LUFS的发生,在自然周期中,排卵前和排卵后人工授精的总体妊娠结果相当。
{"title":"Optimizing timing for intrauterine insemination (IUI) in donor sperm cycles: pre- versus post-ovulation insemination in natural cycles.","authors":"Na Zhang, Hanying Zhou","doi":"10.1080/09513590.2024.2413164","DOIUrl":"https://doi.org/10.1080/09513590.2024.2413164","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate whether pregnancy outcomes of natural cycle intrauterine insemination (IUI) with donor sperm can be improved by performing insemination after confirmation of ovulation.</p><p><strong>Methods: </strong>This retrospective cohort study evaluated 751 couples undergoing 1170 cycles of artificial insemination with donor sperm (AID) in natural cycles between January 2018 and January 2021. Patients underwent AID either within 6-12 h after spontaneous luteinizing hormone (LH) surge (pre-ovulation group) or after ovulation was confirmed by ultrasound (post-ovulation group). Propensity score matching was performed to account for differences in baseline characteristics between groups. The main outcome measures of this study were clinical pregnancy rate and live birth rate.</p><p><strong>Results: </strong>After propensity score matching, each group comprised 216 cycles. No significant differences were observed between the pre-ovulation and post-ovulation groups in terms of clinical pregnancy rate (30.6% vs 27.3%, respectively, <i>p</i> = .458) and live birth rate (25.0% vs 22.7%, respectively, <i>p</i> = .651). However, upon excluding cases of luteinized unruptured follicle syndrome (LUFS) from the pre-ovulation group, the clinical pregnancy rate (33.5% vs 27.3%, respectively, <i>p</i> = .043) and live birth rate (27.4% vs 22.7%, respectively, <i>p</i> = .039) were significantly higher in the pre-ovulation group.</p><p><strong>Conclusions: </strong>For fertile women undergoing AID in natural cycles, pre-ovulation insemination timing yielded superior pregnancy outcomes compared to post-ovulation insemination when ovulation was achieved. However, due to the occurrence of LUFS, pre- and post-ovulation AID resulted in comparable overall pregnancy outcomes in natural cycles.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2413164"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142389857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction. 更正。
IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-12-01 Epub Date: 2024-10-28 DOI: 10.1080/09513590.2024.2421081
{"title":"Correction.","authors":"","doi":"10.1080/09513590.2024.2421081","DOIUrl":"https://doi.org/10.1080/09513590.2024.2421081","url":null,"abstract":"","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2421081"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142499101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hyperandrogenemia impairs endometrial vitamin D receptor expression in polycystic ovary syndrome.
IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-12-01 Epub Date: 2024-12-10 DOI: 10.1080/09513590.2024.2435469
Nur D Gungor, Onder Celik, Ulun Ulug, Nilufer Celik, Aynur Ersahin, Kagan Gungor, Arzu Yurci, Meltem Yardim, Murat Kobaner, Ahmet Tektemur, Tuncay Kuloglu, Ivan Ilkov Maslarski, Sudenaz Celik, Cevdet Duran

Objectives: To determine the effects of hyperandrogenemia and other phenotypic parameters on endometrial vitamin D receptor (VDR-X2 and VDR-X4) expression in women with polycystic ovary syndrome (PCOS) undergoing ovarian stimulation and total embryo freezing.

Methods: Forty-four PCOS patients were divided into four phenotypes according to the criteria for hyperandrogenemia (HA), ovulatory dysfunction (OD), and polycystic ovary morphology (PCOM): phenotype A (HA+OD+PCOM), phenotype B (HA+OD), phenotype C (HA+PCOM), and phenotype D (OD+PCOM). Endometrial VDR expression was determined by real-time PCR and immunohistochemistry. Twenty age- and body mass index (BMI)-matched couples with male infertility were included as controls.

Results: VDR-X2 and VDR-X4 expression levels were significantly lower in the PCOS group than in the control group. A significant downregulation was detected in the relative VDR-X2 and X4 expression in phenotypes A, B, and C compared to the control group. VDR-X2 and X4 expression in phenotype D was significantly higher than in phenotypes A and B. A significant negative correlation was detected among VDR-X2, VDR-X4, serum testosterone (T), androstenedione (A), DHEAS, and insulin resistance (IR). Multivariate analysis revealed that serum T, A, DHEAS, and IR levels were independently associated with both VDR-X2 and VDR X4 relative gene expression after adjusting for age and BMI. The VDR mRNA and immunoreactivity of each phenotype overlapped. The clinical pregnancy rates for each phenotype were similar.

Conclusion: VDR expression in the endometria of patients with PCOS was defective. Hyperandrogenemia and insulin resistance are the key drivers of defective VDR expression in the endometrium of patients with PCOS.

{"title":"Hyperandrogenemia impairs endometrial vitamin D receptor expression in polycystic ovary syndrome.","authors":"Nur D Gungor, Onder Celik, Ulun Ulug, Nilufer Celik, Aynur Ersahin, Kagan Gungor, Arzu Yurci, Meltem Yardim, Murat Kobaner, Ahmet Tektemur, Tuncay Kuloglu, Ivan Ilkov Maslarski, Sudenaz Celik, Cevdet Duran","doi":"10.1080/09513590.2024.2435469","DOIUrl":"https://doi.org/10.1080/09513590.2024.2435469","url":null,"abstract":"<p><strong>Objectives: </strong>To determine the effects of hyperandrogenemia and other phenotypic parameters on endometrial vitamin D receptor (VDR-X2 and VDR-X4) expression in women with polycystic ovary syndrome (PCOS) undergoing ovarian stimulation and total embryo freezing.</p><p><strong>Methods: </strong>Forty-four PCOS patients were divided into four phenotypes according to the criteria for hyperandrogenemia (HA), ovulatory dysfunction (OD), and polycystic ovary morphology (PCOM): phenotype A (HA+OD+PCOM), phenotype B (HA+OD), phenotype C (HA+PCOM), and phenotype D (OD+PCOM). Endometrial VDR expression was determined by real-time PCR and immunohistochemistry. Twenty age- and body mass index (BMI)-matched couples with male infertility were included as controls.</p><p><strong>Results: </strong>VDR-X2 and VDR-X4 expression levels were significantly lower in the PCOS group than in the control group. A significant downregulation was detected in the relative VDR-X2 and X4 expression in phenotypes A, B, and C compared to the control group. VDR-X2 and X4 expression in phenotype D was significantly higher than in phenotypes A and B. A significant negative correlation was detected among VDR-X2, VDR-X4, serum testosterone (T), androstenedione (A), DHEAS, and insulin resistance (IR). Multivariate analysis revealed that serum T, A, DHEAS, and IR levels were independently associated with both VDR-X2 and VDR X4 relative gene expression after adjusting for age and BMI. The VDR mRNA and immunoreactivity of each phenotype overlapped. The clinical pregnancy rates for each phenotype were similar.</p><p><strong>Conclusion: </strong>VDR expression in the endometria of patients with PCOS was defective. Hyperandrogenemia and insulin resistance are the key drivers of defective VDR expression in the endometrium of patients with PCOS.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2435469"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultra-low-dose continuous combined estradiol and dydrogesterone in postmenopausal women: A pooled safety and tolerability analysis. 绝经后妇女超低剂量连续联合雌二醇和地屈孕酮:安全性和耐受性综合分析。
IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-12-01 Epub Date: 2024-07-08 DOI: 10.1080/09513590.2024.2375577
Tetiana Tatarchuk, John C Stevenson, Qi Yu, Elke Kahler, Marcelo Graziano Custodio, Mulan Ren, Rossella E Nappi, Viktoriya Karpova, Tommaso Simoncini

Objective: To assess the safety and tolerability of ultra-low dose estradiol and dydrogesterone (E0.5 mg/D2.5 mg) among postmenopausal women. Methods: This pooled analysis of data from three clinical studies assessed the effects of continuous combined ultra-low-dose estradiol and dydrogesterone among postmenopausal women. Participants received E0.5 mg/D2.5 mg or placebo for 13 weeks (double-blind, randomized, European study), E0.5 mg/D2.5 mg or placebo for 12 weeks (double-blind, randomized, Chinese study), or E0.5 mg/D2.5 mg for 52 weeks (open-label, European study). Safety outcomes included treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (TESAEs), treatment discontinuation due to a TEAE, and adverse events of special interest (AESIs). Results: Overall, 1027 women were included in the pooled analysis (E0.5 mg/D2.5 mg, n = 736; placebo, n = 291). Mean treatment exposure was 288.9 days in the E0.5 mg/D2.5 mg group and 86.6 days in the placebo group. The proportion of women experiencing ≥1 TEAE was similar in the E0.5 mg/D2.5 mg and placebo groups (50.1% vs 49.5%, respectively). TESAEs occurred in 12 (1.6%) women receiving E0.5 mg/D2.5 mg and 9 (3.1%) women receiving placebo. Discontinuation of study treatment was infrequent in both groups (E0.5 mg/D2.5 mg: 1.5%; placebo: 2.4%). The occurrence of breast pain was more common in the E0.5 mg/D2.5 mg group than in the placebo group (2.0% vs 0.3%) as was uterine hemorrhage (6.5% vs 2.4%). The incidence of acne, hypertrichoses and weight increased was similar between groups. Conclusions: Across three studies, ultra-low-dose estradiol plus dydrogesterone was well tolerated among postmenopausal women, with no increase in TEAEs or TESAEs compared with placebo.

目的评估绝经后妇女服用超低剂量雌二醇和地屈孕酮(E0.5 毫克/D2.5 毫克)的安全性和耐受性。方法:本研究对三项临床研究的数据进行了汇总分析,评估了连续联合使用超低剂量雌二醇和地屈孕酮对绝经后妇女的影响。参与者接受 E0.5 毫克/D2.5 毫克或安慰剂治疗 13 周(双盲、随机、欧洲研究),接受 E0.5 毫克/D2.5 毫克或安慰剂治疗 12 周(双盲、随机、中国研究),或接受 E0.5 毫克/D2.5 毫克治疗 52 周(开放标签、欧洲研究)。安全性结果包括治疗突发不良事件(TEAEs)、治疗突发严重不良事件(TESAEs)、因TEAE而中断治疗以及特别关注的不良事件(AESIs)。结果:共有 1027 名妇女被纳入汇总分析(E0.5 mg/D2.5 mg,n = 736;安慰剂,n = 291)。E0.5毫克/D2.5毫克组的平均治疗时间为288.9天,安慰剂组为86.6天。E0.5 mg/D2.5 mg组和安慰剂组出现≥1次TEAE的女性比例相似(分别为50.1% vs 49.5%)。12名(1.6%)接受E0.5 mg/D2.5 mg治疗的女性和9名(3.1%)接受安慰剂治疗的女性发生了TESAE。两组中止研究治疗的情况都不常见(E0.5 毫克/D2.5 毫克:1.5%;安慰剂:2.4%)。与安慰剂组相比,E0.5 毫克/D2.5 毫克组乳房疼痛的发生率更高(2.0% 对 0.3%),子宫出血的发生率也更高(6.5% 对 2.4%)。痤疮、多毛症和体重增加的发生率在各组之间相似。结论在三项研究中,绝经后妇女对超低剂量雌二醇加地屈孕酮的耐受性良好,与安慰剂相比,TEAEs或TESAEs没有增加。
{"title":"Ultra-low-dose continuous combined estradiol and dydrogesterone in postmenopausal women: A pooled safety and tolerability analysis.","authors":"Tetiana Tatarchuk, John C Stevenson, Qi Yu, Elke Kahler, Marcelo Graziano Custodio, Mulan Ren, Rossella E Nappi, Viktoriya Karpova, Tommaso Simoncini","doi":"10.1080/09513590.2024.2375577","DOIUrl":"10.1080/09513590.2024.2375577","url":null,"abstract":"<p><p><b>Objective:</b> To assess the safety and tolerability of ultra-low dose estradiol and dydrogesterone (E0.5 mg/D2.5 mg) among postmenopausal women. <b>Methods:</b> This pooled analysis of data from three clinical studies assessed the effects of continuous combined ultra-low-dose estradiol and dydrogesterone among postmenopausal women. Participants received E0.5 mg/D2.5 mg or placebo for 13 weeks (double-blind, randomized, European study), E0.5 mg/D2.5 mg or placebo for 12 weeks (double-blind, randomized, Chinese study), or E0.5 mg/D2.5 mg for 52 weeks (open-label, European study). Safety outcomes included treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (TESAEs), treatment discontinuation due to a TEAE, and adverse events of special interest (AESIs). <b>Results:</b> Overall, 1027 women were included in the pooled analysis (E0.5 mg/D2.5 mg, <i>n</i> = 736; placebo, <i>n</i> = 291). Mean treatment exposure was 288.9 days in the E0.5 mg/D2.5 mg group and 86.6 days in the placebo group. The proportion of women experiencing ≥1 TEAE was similar in the E0.5 mg/D2.5 mg and placebo groups (50.1% vs 49.5%, respectively). TESAEs occurred in 12 (1.6%) women receiving E0.5 mg/D2.5 mg and 9 (3.1%) women receiving placebo. Discontinuation of study treatment was infrequent in both groups (E0.5 mg/D2.5 mg: 1.5%; placebo: 2.4%). The occurrence of breast pain was more common in the E0.5 mg/D2.5 mg group than in the placebo group (2.0% vs 0.3%) as was uterine hemorrhage (6.5% vs 2.4%). The incidence of acne, hypertrichoses and weight increased was similar between groups. <b>Conclusions:</b> Across three studies, ultra-low-dose estradiol plus dydrogesterone was well tolerated among postmenopausal women, with no increase in TEAEs or TESAEs compared with placebo.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2375577"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Statement of Retraction: L-Carnitine plus metformin in clomiphene-resistant obese PCOS women, reproductive and metabolic effects: a randomized clinical trial. 撤回声明:左旋肉碱加二甲双胍治疗克罗米芬抵抗性肥胖多囊卵巢综合征妇女,生殖和代谢影响:随机临床试验。
IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-12-01 Epub Date: 2024-11-02 DOI: 10.1080/09513590.2024.2419767
{"title":"Statement of Retraction: L-Carnitine plus metformin in clomiphene-resistant obese PCOS women, reproductive and metabolic effects: a randomized clinical trial.","authors":"","doi":"10.1080/09513590.2024.2419767","DOIUrl":"https://doi.org/10.1080/09513590.2024.2419767","url":null,"abstract":"","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2419767"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of SOGPI in mediating the effect of Phosphatidylcholine on polycystic Ovary Syndrome. SOGPI与磷脂酰胆碱对多囊卵巢综合征的作用有关。
IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-12-01 Epub Date: 2024-10-26 DOI: 10.1080/09513590.2024.2420963
Qian Guo, Wei Wang, Jie Chen, Wei-Rong Ma, Yingqian Yang, Yong Tan

Background: Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder in women of reproductive age, marked by hormonal imbalances and disruptions in glucose and lipid metabolism. Emerging research has indicated a correlation between lipids and PCOS, yet the specific lipid profiles or associated genes identified in various studies vary, and observational data alone cannot establish causation. Therefore, our study seeks to establish a causal association between lipidome and PCOS.

Methods: Data from genome-wide association studies, liposomes, metabolites, and PCOS-related information were collected. Four rounds of double-sample bidirectional intermediate Mendelian Randomization analyses including liposomes to disease, liposomes to metabolites, metabolites to disease, and reverse Mendelian Randomization analysis of lipids, total effect values and intermediary effect values were calculated. The proportion mediated by the intermediary effect was determined by dividing the intermediary effect value by the total effect value.

Results: The analyses revealed that three liposomes and nine metabolites were causally associated with PCOS. Specifically, phosphatidylcholine and 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol were identified as independent risk factors for PCOS through further Mendelian Randomization analysis. The risk of developing PCOS increased by 32% for every one standard deviation increase in phosphatidylcholine and by 17% for every one standard deviation increase in 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol. Furthermore, the study revealed that phosphatidylcholine can influence the development of PCOS with 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol acting as a mediator, explaining 4.97% of the effect.

Conclusions: This study confirmed a causal relationship between phosphatidylcholine and 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol with PCOS, where phosphatidylcholine can influence the occurrence of PCOS with 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol as a mediator.

背景:多囊卵巢综合征(PCOS)是育龄妇女普遍存在的一种内分泌失调症,主要表现为内分泌失调以及葡萄糖和脂质代谢紊乱。新近的研究表明,血脂与多囊卵巢综合征之间存在相关性,但不同研究中发现的具体血脂特征或相关基因各不相同,仅凭观察数据无法确定因果关系。因此,我们的研究试图确定脂质体与多囊卵巢综合症之间的因果关系:方法:收集来自全基因组关联研究、脂质体、代谢物和多囊卵巢综合征相关信息的数据。进行四轮双样本双向中间孟德尔随机分析,包括脂质体与疾病、脂质体与代谢物、代谢物与疾病,以及脂质体的反向孟德尔随机分析,计算总效应值和中间效应值。中间效应介导的比例由中间效应值除以总效应值得出:结果:分析表明,3 种脂质体和 9 种代谢物与多囊卵巢综合征有因果关系。通过进一步的孟德尔随机分析,磷脂酰胆碱和 1-硬脂酰-2-油酰-糖基磷脂酰肌醇被确定为多囊卵巢综合征的独立危险因素。磷脂酰胆碱每增加一个标准差,患多囊卵巢综合症的风险就会增加 32%;1-硬脂酰-2-油酰-糖基磷脂酰肌醇每增加一个标准差,患多囊卵巢综合症的风险就会增加 17%。此外,研究还发现,磷脂酰胆碱可影响多囊卵巢综合征的发展,而 1-硬脂酰-2-油酰基-糖基磷脂酰肌醇则是影响多囊卵巢综合征的中介物质,可解释 4.97% 的影响:该研究证实了磷脂酰胆碱和1-硬脂酰-2-油酰基-糖基磷脂酰肌醇与多囊卵巢综合征之间的因果关系,其中磷脂酰胆碱可影响多囊卵巢综合征的发生,而1-硬脂酰-2-油酰基-糖基磷脂酰肌醇则是影响多囊卵巢综合征的介质。
{"title":"Association of SOGPI in mediating the effect of Phosphatidylcholine on polycystic Ovary Syndrome.","authors":"Qian Guo, Wei Wang, Jie Chen, Wei-Rong Ma, Yingqian Yang, Yong Tan","doi":"10.1080/09513590.2024.2420963","DOIUrl":"10.1080/09513590.2024.2420963","url":null,"abstract":"<p><strong>Background: </strong>Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder in women of reproductive age, marked by hormonal imbalances and disruptions in glucose and lipid metabolism. Emerging research has indicated a correlation between lipids and PCOS, yet the specific lipid profiles or associated genes identified in various studies vary, and observational data alone cannot establish causation. Therefore, our study seeks to establish a causal association between lipidome and PCOS.</p><p><strong>Methods: </strong>Data from genome-wide association studies, liposomes, metabolites, and PCOS-related information were collected. Four rounds of double-sample bidirectional intermediate Mendelian Randomization analyses including liposomes to disease, liposomes to metabolites, metabolites to disease, and reverse Mendelian Randomization analysis of lipids, total effect values and intermediary effect values were calculated. The proportion mediated by the intermediary effect was determined by dividing the intermediary effect value by the total effect value.</p><p><strong>Results: </strong>The analyses revealed that three liposomes and nine metabolites were causally associated with PCOS. Specifically, phosphatidylcholine and 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol were identified as independent risk factors for PCOS through further Mendelian Randomization analysis. The risk of developing PCOS increased by 32% for every one standard deviation increase in phosphatidylcholine and by 17% for every one standard deviation increase in 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol. Furthermore, the study revealed that phosphatidylcholine can influence the development of PCOS with 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol acting as a mediator, explaining 4.97% of the effect.</p><p><strong>Conclusions: </strong>This study confirmed a causal relationship between phosphatidylcholine and 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol with PCOS, where phosphatidylcholine can influence the occurrence of PCOS with 1-Stearoyl-2-Oleoyl-Glycosylphosphatidylinositol as a mediator.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2420963"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142499100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Gynecological Endocrinology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1